Intermittent Low Oxygen Breathing: A First Study Testing Different Disease Stages in People Living With MS

Sponsor
University of Saskatchewan
Study ID
NCT07631143
Phase
PHASE1/PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Acute Intermittent Hypoxia — OTHER
    Hypoxia (10% O2) will be administered via a non-rebreather face mask connected to an oxygen tank supplying the 10% O2. Each session will involve 15 cycles of hypoxia, each lasting 90 seconds, interspersed with 60 second cycles of normoxia. The total duration of each session will be approximately 37 minutes. An inline oxygen analyzer will allow recording of the percentage of oxygen being delivered. A fingertip pulse-oximeter will be worn throughout to ensure that oxygen saturation (SpO2) falls to a nadir between 80 - 87% during hypoxic episodes and heart rate monitoring will be performed. Blood pressure will be checked prior to and following each session (within 5 minutes of treatment cessation).

Study Details

This study will look at the safety, tolerability and feasibility of a non-invasive treatment called Acute Intermittent Hypoxia (AIH) in people with Multiple Sclerosis (MS) at different stages of the disease course.

Key Dates

First listed
Jun 5, 2026
Start date
Jul 1, 2026
Status verified
Jun 2026
Primary completion
Aug 1, 2028
Completion
Aug 1, 2028

Study Design

Enrollment
9 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment
    Acute Intermittent Hypoxia

Primary Outcome Measure

SpO2 < 78%, Heart rate < 50 beats per minute (bpm) or > 160 bpm [ Time Frame: During the six AIH treatment session in weeks 1-4 ]

Central Contacts

Find similar trials

Nationwide
Multiple sclerosis trialsNeurology trialsBrain disorders trialsAutoimmune disease trials

Related Studies